Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$7.61 -1.6%	$7.71	$6.67 ▼ $27.90	$8.07M	1.76	93,710 shs	1,017 shs
ATHE Alterity Therapeutics	$3.56	$3.90	$1.00 ▼ $5.87	$31.57M	0.61	151,713 shs	10,843 shs
OVID Ovid Therapeutics	$0.38 -6.9%	$0.58	$0.37 ▼ $3.45	$26.93M	0.29	411,152 shs	500,310 shs
PASG Passage Bio	$0.41 -10.2%	$0.52	$0.35 ▼ $1.64	$25.68M	1.55	330,002 shs	185,881 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-0.78%	+2.70%	-5.47%	+1.20%	-38.38%
ATHE Alterity Therapeutics	0.00%	-9.18%	-14.71%	+13.38%	+76.24%
OVID Ovid Therapeutics	-6.90%	-12.01%	-33.14%	-60.95%	-87.58%
PASG Passage Bio	-10.19%	-13.19%	-21.61%	-37.11%	-68.46%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.8135 of 5 stars	3.5	5.0	0.0	3.3	0.8	0.0
ATHE Alterity Therapeutics	2.7487 of 5 stars	3.3	5.0	0.0	3.0	1.7	0.0
OVID Ovid Therapeutics	4.5317 of 5 stars	3.5	3.0	4.6	2.4	4.2	0.6
PASG Passage Bio	3.2884 of 5 stars	3.5	4.0	0.0	2.7	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	294.22% Upside
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	237.08% Upside
OVID Ovid Therapeutics	3.00	Buy	$3.03	700.56% Upside
PASG Passage Bio	3.00	Buy	$7.50	1,715.10% Upside

Current Analyst Ratings Breakdown

Latest ADXN, OVID, ATHE, and PASG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	OVID Ovid Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
3/12/2025	OVID Ovid Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $3.00
3/4/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
2/3/2025	ATHE Alterity Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Speculative Buy ➝ Hold
1/30/2025	ATHE Alterity Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$8.00 ➝ $12.00
1/29/2025	OVID Ovid Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$556.05K	14.51	N/A	N/A	$1.20 per share	6.34
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
OVID Ovid Therapeutics	$566K	47.58	N/A	N/A	$1.24 per share	0.31
PASG Passage Bio	N/A	N/A	N/A	N/A	$2.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	-$11.76M	-$0.34	N/A	∞	N/A	850.30%	-112.43%	-77.95%	4/7/2025 (Estimated)
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	-$52.34M	-$0.38	N/A	N/A	N/A	-5,142.56%	-39.24%	-26.19%	5/13/2025 (Estimated)
PASG Passage Bio	-$102.06M	-$1.07	N/A	N/A	N/A	N/A	-72.53%	-52.10%	5/13/2025 (Estimated)

Latest ADXN, OVID, ATHE, and PASG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2025	Q4 2024	OVID Ovid Therapeutics	-$0.16	-$0.13	+$0.03	-$0.13	$0.19 million	$0.08 million
3/4/2025	Q4 2024	PASG Passage Bio	-$0.21	-$0.20	+$0.01	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	4.59	4.59
ATHE Alterity Therapeutics	N/A	3.54	3.54
OVID Ovid Therapeutics	0.18	5.66	5.66
PASG Passage Bio	N/A	5.15	5.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
ATHE Alterity Therapeutics	2.14%
OVID Ovid Therapeutics	72.24%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
ATHE Alterity Therapeutics	38.80%
OVID Ovid Therapeutics	13.30%
PASG Passage Bio	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.35 million	Not Optionable
OVID Ovid Therapeutics	60	71.08 million	61.57 million	Optionable
PASG Passage Bio	130	62.15 million	59.11 million	Optionable

ADXN, OVID, ATHE, and PASG Headlines

Recent News About These Companies

L'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$

March 14, 2025 | fr.investing.com

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

March 7, 2025 | zacks.com

PASSAGE BIO, INC. : Chardan Research reste à l'achat

March 5, 2025 | zonebourse.com

L’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$

March 5, 2025 | fr.investing.com

Passage Bio price target lowered to $6 from $7 at Chardan

March 5, 2025 | markets.businessinsider.com

Passage Bio publie ses résultats du quatrième trimestre et de l'année 2024.

March 4, 2025 | zonebourse.com

Passage Bio reports FY24 EPS ($1.07) vs ($1.86) last year

March 4, 2025 | markets.businessinsider.com

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

March 4, 2025 | globenewswire.com

Passage Bio to Participate in Upcoming Investor Conferences

February 26, 2025 | globenewswire.com

Passage Bio will again trim workforce in latest cost-cutting move

February 16, 2025 | bizjournals.com

La directrice financière de Passage Bio cède des actions pour 1.685$

February 12, 2025 | fr.investing.com

Passage Bio CFO sells shares worth $1,685

February 12, 2025 | msn.com

Les actions de Passage Bio passent au Nasdaq Capital Market

February 1, 2025 | fr.investing.com

Passage Bio shares transition to Nasdaq Capital Market

February 1, 2025 | msn.com

Insider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 17,986 Shares of Stock

January 15, 2025 | insidertrades.com

Orbimed advisors réduit sa participation dans Passage Bio pour 142.223$

January 14, 2025 | fr.investing.com

Passage Bio Cutting 55% of Staff to Help Extend Cash Runway

January 13, 2025 | biospace.com

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment

January 11, 2025 | msn.com

IGM, Y-mAbs, Passage Bio and more telegraph staff cuts amid restructuring spree

January 10, 2025 | fiercebiotech.com

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

January 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

How to Build the Ultimate Everything ETF Portfolio
By Jeffrey Neal Johnson | March 16, 2025
View How to Build the Ultimate Everything ETF Portfolio
Best of Both Worlds: 3 ETFs With High Dividend Yields, Low Fees
By Nathan Reiff | March 26, 2025
View Best of Both Worlds: 3 ETFs With High Dividend Yields, Low Fees
What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
By Thomas Hughes | March 19, 2025
View What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
Is Intuitive Machines a Buy After Athena's Disappointing Landing?
By Leo Miller | March 18, 2025
View Is Intuitive Machines a Buy After Athena's Disappointing Landing?
Tempus AI Is a Buy, If You Can Handle the Volatility
By Thomas Hughes | February 26, 2025
View Tempus AI Is a Buy, If You Can Handle the Volatility

ADXN, OVID, ATHE, and PASG Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$7.64 -0.09 (-1.11%)

As of 03/27/2025 04:00 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Alterity Therapeutics NASDAQ:ATHE

$3.56 0.00 (0.00%)

Closing price 03/27/2025 03:45 PM Eastern

Extended Trading

$3.44 -0.12 (-3.37%)

As of 03/27/2025 06:42 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Ovid Therapeutics NASDAQ:OVID

$0.38 -0.03 (-6.90%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-0.24%)

As of 03/27/2025 07:13 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Passage Bio NASDAQ:PASG

$0.41 -0.05 (-10.19%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.92%)

As of 03/27/2025 07:39 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time